Paliperidone ER and oral risperidone in patients with schizophrenia: a comparative database analysis
2011

Comparing Paliperidone ER and Risperidone for Schizophrenia

Sample size: 933 publication Evidence: moderate

Author Information

Author(s): Turkoz Ibrahim, Bossie Cynthia A, Lindenmayer Jean-Pierre, Schooler Nina, Canuso Carla M

Primary Institution: Johnson & Johnson Pharmaceutical Research and Development, LLC

Hypothesis

To compare the efficacy and tolerability of paliperidone extended-release (ER) with risperidone immediate-release using propensity score methodology.

Conclusion

Paliperidone ER 6-12 mg/day may be more effective than risperidone 2-4 mg/day and equally effective as risperidone 4-6 mg/day.

Supporting Evidence

  • Completion rates for paliperidone ER were 64.8%, while for risperidone 2-4 mg/day it was 54.0%.
  • Paliperidone ER showed a greater improvement in PANSS total score compared to risperidone 2-4 mg/day.
  • Response rates were 55.1% for paliperidone ER compared to 40.7% for risperidone 2-4 mg/day.

Takeaway

This study looked at two medications for schizophrenia and found that one might work better than the other for some patients.

Methodology

The study used propensity score matching to compare data from six randomized, placebo-controlled trials.

Potential Biases

The nonrandomized design may limit the clinical interpretation of results.

Limitations

Differences in trial design and patient demographics may introduce bias.

Participant Demographics

Adults aged 18-65 with schizophrenia, with a mix of prior treatments.

Statistical Information

P-Value

0.005

Statistical Significance

p<0.05

Digital Object Identifier (DOI)

10.1186/1471-244X-11-21

Want to read the original?

Access the complete publication on the publisher's website

View Original Publication